Idiopathic Pulmonary Fibrosis (IPF) is an interstitial lung disease with no known cause or cure. IPF has an incidence of 75/1,000,000 of the population, predominately in men over the age of 60. This relatively rare disease develops in a chronic and progressive way, ultimately leading to death within two to five years of diagnosis. Our use of translatable methodologies in the bleomycin mouse model of IPF led to the novel identification of the similarities between the average percent loss of lung function in previous human clinical trials to that of our mouse model data. There is no treatment for IPF outside of lung transplantation, therefore our goal is to develop a protein therapy to halt the progression of IPF. B6_BP_dslf is a small, 93.36 kDa minibinder protein with a nanomolar affinity to αvβ6, an integrin of therapeutic potential for IPF when inhibited by halting αvβ6/TGF-β signaling. Our hypothesis is that B6_BP_dslf will halt the progression of pulmonary fibrosis induced in a mouse model of IPF. To test this hypothesis, a de novo design method was used resulting in the B6_BP_dslf minibinder having high β unit selectivity and nanomolar affinity for αvβ6, and maintenance of its secondary structure after aerosolization. These attributes led to testing in the bleomycin mouse model for IPF as an inhaled therapy. We found that B6_BP_dslf inhalation by mice with induced pulmonary fibrosis had reduced pathogenesis through the quantification of biomarkers for αvβ6/TGF-β mediated fibrosis, lowered histopathological scores, and improved lung function. These positive results from standard biochemical analysis and clinically translatable methods show that BP_B6_dslf has clinical potential as an inhaled therapy for IPF. Additionally, we tested the use of lung function tests in an animal model of chronic obstructive pulmonary disease (COPD), using secondhand smoke exposure to induce the disease and to identify inflammatory pathways. We found that smoke exposure increased inflammatory signaling through receptors for advanced glycation end-products, and inhibition of these receptors using a novel therapy of semi-synthetic glycosaminoglycan ethers (SAGEs) reduced inflammation and improved lung function. Together, the data from two different lung disease models supports the use of lung function as a preclinical efficacy variable for experimental drugs. The combination of biochemical and functional assessments of B6_BP_dslf and SAGEs gives weight to their therapeutic potential.

No description available.

Bakgrund: Vid idiopatisk lungfibros (IPF) är dyspné det dominerande symtomet, vilket påverkar gångsträckan. Andra patientkategorier har ökat gångsträckan och minskat dyspnén efter inspirationsmuskelträning (IMT). Endast två studier angående IMT för personer med IPF har hittats och ingen av dessa studier har IMT som enda studieintervention.   Syfte: Syftet var att undersöka om IMT ökar andningsmuskelstyrkan (MIP), om gångsträcka och dyspné förändras efter träningen samt om det finns ett samband mellan MIP och gångsträcka, MIP och dyspné samt gångsträcka och dyspné.   Metod: Single-subject experimentell design användes. Sex personer med IPF deltog. IMT genomfördes under åtta veckor. Under baslinje, intervention och cirka sex veckor efter interventionsslutet mättes MIP med Micro RPM® och gångsträcka med sex-minuters gångtest. Dyspnén skattades med Borg CR-10-skala och University of California San Diego Shortness of Breath Questionnaire (UCSD SOBQ).   Resultat: Resultatet varierade mellan studiedeltagarna. Fyra deltagare ökade MIP. Fem studiedeltagare hade en kliniskt relevant ökning av gångsträcka. Fyra deltagare hade en kliniskt relevant minskad dyspné vid skattning med Borg CR-10 i vila eller UCSD SOBQ. Korrelationen mellan MIP och gångsträcka var signifikant för två studiedeltagare med rs 0,88 respektive 0,99.   Konklusion: IMT kan öka MIP och ge kliniskt relevanta förbättringar av gångsträcka och dyspné. Alla studiedeltagare drar ej nytta av träningen. Fortsatta studier behövs för att undersöka vilka som har nytta av IMT och vilken träningsmängd som behövs för att uppnå förbättring. / Introduction: In idiopathic pulmonary fibrosis (IPF), dyspnoea is the predominant symptom that affects walking distance. In other patient categories, walking distance has been increased and dyspnoea has been reduced after inspiratory muscle training (IMT). Only two studies on IMT for people with IPF have been found and none of these studies have IMT as the sole study intervention. Purpose: The purpose was to investigate whether IMT increases respiratory muscle strength (MIP), if walking distance and dyspnoea alter after practice, and if there is a relation between MIP and walking distance, MIP and dyspnoea and walking distance and dyspnoea. Method: Single-subject experimental design was used. Six people with IPF participated. IMT was carried out in eight weeks. During baseline, intervention and about six weeks after the intervention, MIP was measured with Micro RPM® and walking distance with a six-minute walk test. Dyspnoea was estimated with Borg CR 10-scale and the University of California, San Diego Shortness of Breath Questionnaire (UCSD SOBQ). Results: The results varied among the study participants. For four participants, the MIP increased. Five study participants had a clinically relevant increase in walking distance. Four participants had a clinically relevant reduction in dyspnoea on measuring with Borg CR 10 at rest or UCSD SOBQ. The correlation between MIP and walking distance was significant for two study participants with rs 0.88 and 0.99, respectively. Conclusion: IMT can increase MIP and provide clinically relevant improvements in walking distance and dyspnoea. All study participants do not benefit from exercise. Further studies are needed to determine which ones have the advantage of IMT and the amount of exercise needed to achieve improvement.

La Fibrose Pulmonaire Idiopathique (FPI) est une maladie dévastatrice, d’étiologie inconnue, qui reste pour le moment incurable. Cette maladie est caractérisée par l’accumulation de fibroblastes et de protéines de la matrice extracellulaire dans les espaces aériens distaux aboutissant à une destruction alvéolaire et à une altération des propriétés mécaniques du poumon. La physiopathologie de la FPI est mal connue mais de nombreuses études suggèrent que la réactivation des voies impliquées dans le développement contribue à l’accumulation de la matrice extra-cellulaire et au comportement anormal des cellules épithéliales et des fibroblastes.La voie Hedgehog (HH) joue un rôle crucial dans le développement embryonnaire. Dans le développement pulmonaire fœtal, la voie HH est impliquée dans les interactions épithélium-fibroblaste et contrôle la prolifération et la différenciation du mésenchyme. La voie HH a été impliquée dans la fibrogénèse, notamment dans le foie et le rein.L’objectif de cette thèse a été de caractériser la voie HH dans la fibrose pulmonaire chez l’homme et dans un modèle de fibrose induite par la bléomycine chez la souris.Nous avons démontré que la voie HH est réactivée dans les tissus pulmonaires de patients atteints de FPI et dans le modèle de fibrose pulmonaire chez la souris. Nous avons montré que le TGF-β1 activait la voie HH dans les fibroblastes pulmonaires humains et que l’inhibition pharmacologique de la voie HH au niveau des facteurs GLI inhibait l’effet du TGF-β1 in vitro. Par contre, ces inhibiteurs ne protégent pas les cellules épithéliales alvéolaires de la transition épithélio-mésenchymateuse induite par le TGF-β1. In vivo, chez la souris, nous avons montré que le traitement par des inhibiteurs de Smoothened ne protégeait pas du développement de la fibrose tandis que le GANT61, un inhibiteur de l’interaction des GLI avec l’ADN, inhibait la fibrose.En conclusion, nos résultats démontrent l’implication de la voie HH dans la fibrose pulmonaire et ouvrent des perspectives thérapeutiques nouvelles. / Idiopathic Pulmonary Fibrosis (IPF ) is a devastating disease of unknown etiology, which no efficient treatment. This disease is characterized by the accumulation of fibroblasts and extracellular matrix proteins in the distal airways resulting to the destruction of alveoli and alteration of mechanical properties of the lung. The pathogenesis of IPF is not well known but many studies suggest that reactivation of pathways involved in the development, contributes to the accumulation of extracellular matrix and the abnormal behavior of epithelial cells and fibroblasts.The Hedgehog pathway (HH) plays a crucial role in embryonic development. In the fetal lung development, the HH pathway is involved in the epithelial-fibroblast interactions and controls the proliferation and differentiation of the mesenchyme. The HH pathway has been implicated in the fibrogenesis, particularly in the liver and kidney.The aim of this thesis was to characterize the HH pathway in pulmonary fibrosis in humans and in a model of bleomycin-induced fibrosis in mice.We demonstrated that the HH pathway is reactivated in lung tissue of IPF patients and in the model of pulmonary fibrosis in mice. We have shown that TGF-β1 activated the HH pathway in human lung fibroblasts and that the pharmacological inhibition of the HH pathway at the level of GLI transcription factors, inhibited the effect of TGF-β1 in vitro. By contrast, these inhibitors did not protect alveolar epithelial cells from TGF-β1-induced epithelial-mesenchymal transition. In vivo, we have shown that treatment with Smoothened inhibitors did not protect mice from the development of fibrosis while GANT61, an inhibitor of the GLI interaction with DNA, inhibited fibrosis .In conclusion, our results demonstrate the involvement of the HH pathway in pulmonary fibrosis and open new therapeutic perspectives.

Introdução: A fibrose pulmonar idiopática (FPI) é definida como um tipo de doença fibrosante intersticial crônica de etiologia desconhecida limitada aos pulmões e que apresenta padrão histológico de pneumonia intersticial usual. A prevalência de FPI é estimada em, aproximadamente, 20/100.000 em homens e em 13/100.000 em mulheres, sendo que a idade média do diagnóstico é 67 anos e a sobrevivência média é 2 a 5 anos. Estima-se que 5 milhões de pessoas sejam afetadas em todo o mundo. O tratamento clínico atual está associado com melhora parcial e transitória, com resultados duvidosos ou insatisfatórios. Na abordagem cirúrgica da FPI, tem destaque o transplante pulmonar, cuja realização é rara, devido à escassez de doadores e à limitação das equipes capazes de realizar tais procedimentos. A terapia celular é uma alternativa terapêutica com grande potencial de aplicabilidade na fibrose pulmonar. Objetivos: Utilizar um modelo de fibrose pulmonar induzida pela bleomicina em ratos para investigar os efeitos da terapia com células-tronco mesenquimais (CTM) e o meio condicionado no remodelamento pulmonar com objetivo de elucidar o mecanismo de ação das CTM e meio condicionado, na reversão da fibrose pulmonar. Para tanto, buscamos: 1) padronizar a cultura de células-tronco mesenquimais e meio de cultura; 2) caracterizar o modelo experimental de fibrose pulmonar induzida pela bleomicina por microscopia óptica antes e após o tratamento com CTM e meio de cultura; 3) avaliar a expressão de biomarcadores sorológicos (Fibrinogênio, Fator von Willebrand e PDGF); 4) quantificar a expressão de proteínas relacionadas ao estresse oxidativo (NOS), citocinas pró-inflamatórias e pró-fibróticas (IL-17 e TGF-beta) e pró-angiogênicas (VEGF e endotelina) por imuno-histoquímica; e 5) quantificar a deposição de fibras do colágeno I e V por imunofluorescência. Materiais e Métodos: Utilizou-se um total de 44 ratos Wistar machos albinos com peso médio de 250-300g e 8 semanas de idade. Quatro grupos experimentais foram compostos de 10 animais, que participaram do experimento divididos em três momentos: D0, D10 e eutanásia (D14 ou D21). Em D0, foi realizada a instilação orotraqueal de bleomicina na dose de 1,5 U/kg; em D10, foi realizada a infusão em veia caudal de células-tronco mesenquimais na dose de 106 CTM/Kg ou 200 ?l de meio condicionado. Para o preparo das CTM, foi obtido, em média, 1,2 g de tecido adiposo, procedida a dissociação com colagenase tipo I, sendo que a contagem média de células foi de 3,05 x 106 células linfomononucleares/g de tecido adiposo. Estas células foram cultivadas durante 21 dias em meio Knockout DMEM-F12 suplementado com 10% de soro fetal bovino. Os seguintes três critérios foram utilizados para comprovar o perfil das células-tronco mesenquimais: aderência plástica, expressão de CD90 por citometria de fluxo ( > 90%) e capacidade de diferenciação em três linhagens mesodérmicas. Em D10, um pool destas células alogênicas foi infundido intravenosamente, na veia caudal, a uma concentração de 1 x 106 células/ animal num volume de 200 ul de solução salina. Em D14 ou D21, os animais foram eutanasiados e analisados quanto ao peso e conforme análises microscópico-laboratoriais. As análises histológicas foram realizadas por dois especialistas diferentes em estudo duplo-cego. Os parâmetros de ganho de peso e recuperação microscópica do tecido pulmonar foram analisados em cada grupo. Resultados: Nossos dados mostram que as células-tronco mesenquimais oriundas do tecido adiposo abdominal de ratos Wistar tiveram seu perfil fenotípico, capacidade de adesão plástica e diferenciação em 3 linhagens mesodérmicas estabelecidas inequivocamente, conforme estabelecido internacionalmente pela ISSCR. As células-tronco mesenquimais e o meio condicionado induziram: a recuperação clínica após tratamento; a reversão da inflamação e de fibrose pulmonar induzida pela bleomicina; a reversão da arteriopatia no parênquima pulmonar distal; a redução das concentrações de fibrinogênio, fator von Willebrand e PDGF (marcadores sorológicos); a diminuição da expressão de enzimas oxidantes; a diminuição da expressão de endotelina e a modulação da expressão da proteína de remodelamento (IL-17), da ativação dos fibroblastos TGF-B e da síntese de colágeno. Conclusão: Neste estudo, comprovamos que as terapias com células-tronco mesenquimais derivadas do tecido adiposo e com o meio condicionado foram eficazes na modulação dos processos inflamatórios e fibrogênicos no modelo induzido por bleomicina, agindo na ativação miofibroblástica, e, também, na restauração tecidual e endotelial. Além disso, o meio condicionado se mostrou tão eficiente quanto as células-tronco propriamente ditas, no efetivo remodelamento pulmonar, devendo ser considerado como uma proposta terapêutica viável e inovadora / Introduction: Idiopathic pulmonary fibrosis (IPF) is defined as a type of chronic interstitial fibrosing disease of unknown etiology limited to the lungs and presenting a histological pattern of usual interstitial pneumonia. The prevalence of IPF is estimated at approximately 20/100,000 in men and 13/100,000 in women, with the mean age of diagnosis being 67 years and the average survival is 2 to 5 years. It is estimated that 5 million people are affected worldwide. The current clinical treatment is associated with partial and transient improvement, with dubious or unsatisfactory results. In the surgical approach to IPF, pulmonary transplantation is a prominent feature, which is rare because of the scarcity of donors and the limitation of the teams capable of performing such procedures. Cell therapy is a therapeutic alternative with great potential for applicability in pulmonary fibrosis. Objectives: To use a model of bleomycin-induced lung fibrosis in rats to investigate the effects of mesenchymal stem cell (MSC) therapy and conditioned medium on lung remodeling in order to elucidate the mechanism of action of MSC and conditioned medium, in the reversion of pulmonary fibrosis. To do so, we aim to: 1) standardize the culture of mesenchymal stem cells and conditioned medium; 2) characterize the experimental model of lung fibrosis induced by bleomycin by optical microscopy before and after treatment with MSC and conditioned medium; 3) to evaluate the expression of serological biomarkers (Fibrinogen, Factor von Willebrand and PDGF); 4) to quantify the expression of proteins related to oxidative stress (NOS), pro-inflammatory and pro-fibrotic (IL-17 and TGF-beta) and pro-angiogenic cytokines (VEGF and endothelin) by immunohistochemistry; and 5) to quantify the deposition of collagen I and V fibers by immunofluorescence. Materials and methods: A total of 44 male albino Wistar rats weighing 250-300g and 8 weeks of age were used. Four experimental groups were composed of 10 animals, which participated in the experiment divided in three moments: D0, D10 and euthanasia (D14 or D21). In D0, orotracheal instillation of bleomycin at the dose of 1.5 U/ kg was performed; in D10 caudal vein infusion of mesenchymal stem cells at the dose of 106 MSC/ kg or 200 ul of conditioned medium was performed. To prepare the MSC, a mean of 1.2 g of adipose tissue was obtained, dissociated with type I collagenase and the mean cell count was 3.05 x 106 lymphomonuclear cells / g of adipose tissue. These cells were cultured for 21 days in DMEM-F12 Knockout medium supplemented with 10% fetal bovine serum. The following three criteria were used to prove the profile of mesenchymal stem cells: plastic adherence, expression of CD90 by flow cytometry ( > 90%) and differentiation capacity in three mesodermal lines. In D10, a pool of these allogeneic cells was infused intravenously into the caudal vein at a concentration of 1 x 106 cells / animal in a volume of 200 ul of saline. In D14 or D21 the animals were euthanized and analyzed for weight and microscopic-laboratory analyzes. Histological analyzes were performed by two different specialists in a double-blind study. The parameters of weight gain and microscopic recovery of lung tissue were analyzed in each group. Results: Our data show that the mesenchymal stem cells derived from the abdominal adipose tissue of Wistar rats had their phenotypic profile, plastic adhesion capacity and differentiation in 3 mesodermal lines established unequivocally, as established internationally by ISSCR. Mesenchymal stem cells and conditioned medium induced: clinical recovery after treatment; bleomycin-induced reversal of inflammation and pulmonary fibrosis; the reversal of arteriopathy in the distal pulmonary parenchyma; the reduction of fibrinogen, von Willebrand factor and PDGF concentrations (serologic markers); decreased expression of oxidizing enzymes; the reduction of endothelin expression and the modulation of the expression of the remodeling protein (IL-17), the activation of TGF-B fibroblasts and the synthesis of collagen. Conclusion: In this study we demonstrated that therapies with mesenchymal stem cells derived from adipose tissue and conditioned medium were effective in the modulation of inflammatory and fibrogenic processes in the bleomycin-induced model, acting to modulate myofibroblastic activation and also in tissue restoration and endothelial cells. In addition, the conditioned medium proved to be as efficient as the stem cells themselves, in effective pulmonary remodeling, and should be considered as a viable and innovative therapeutic proposal

Introdução: A fibrose pulmonar idiopática (FPI) é definida como um tipo de doença fibrosante intersticial crônica de etiologia desconhecida limitada aos pulmões e que apresenta padrão histológico de pneumonia intersticial usual. A prevalência de FPI é estimada em, aproximadamente, 20/100.000 em homens e em 13/100.000 em mulheres, sendo que a idade média do diagnóstico é 67 anos e a sobrevivência média é 2 a 5 anos. Estima-se que 5 milhões de pessoas sejam afetadas em todo o mundo. O tratamento clínico atual está associado com melhora parcial e transitória, com resultados duvidosos ou insatisfatórios. Na abordagem cirúrgica da FPI, tem destaque o transplante pulmonar, cuja realização é rara, devido à escassez de doadores e à limitação das equipes capazes de realizar tais procedimentos. A terapia celular é uma alternativa terapêutica com grande potencial de aplicabilidade na fibrose pulmonar. Objetivos: Utilizar um modelo de fibrose pulmonar induzida pela bleomicina em ratos para investigar os efeitos da terapia com células-tronco mesenquimais (CTM) e o meio condicionado no remodelamento pulmonar com objetivo de elucidar o mecanismo de ação das CTM e meio condicionado, na reversão da fibrose pulmonar. Para tanto, buscamos: 1) padronizar a cultura de células-tronco mesenquimais e meio de cultura; 2) caracterizar o modelo experimental de fibrose pulmonar induzida pela bleomicina por microscopia óptica antes e após o tratamento com CTM e meio de cultura; 3) avaliar a expressão de biomarcadores sorológicos (Fibrinogênio, Fator von Willebrand e PDGF); 4) quantificar a expressão de proteínas relacionadas ao estresse oxidativo (NOS), citocinas pró-inflamatórias e pró-fibróticas (IL-17 e TGF-beta) e pró-angiogênicas (VEGF e endotelina) por imuno-histoquímica; e 5) quantificar a deposição de fibras do colágeno I e V por imunofluorescência. Materiais e Métodos: Utilizou-se um total de 44 ratos Wistar machos albinos com peso médio de 250-300g e 8 semanas de idade. Quatro grupos experimentais foram compostos de 10 animais, que participaram do experimento divididos em três momentos: D0, D10 e eutanásia (D14 ou D21). Em D0, foi realizada a instilação orotraqueal de bleomicina na dose de 1,5 U/kg; em D10, foi realizada a infusão em veia caudal de células-tronco mesenquimais na dose de 106 CTM/Kg ou 200 ?l de meio condicionado. Para o preparo das CTM, foi obtido, em média, 1,2 g de tecido adiposo, procedida a dissociação com colagenase tipo I, sendo que a contagem média de células foi de 3,05 x 106 células linfomononucleares/g de tecido adiposo. Estas células foram cultivadas durante 21 dias em meio Knockout DMEM-F12 suplementado com 10% de soro fetal bovino. Os seguintes três critérios foram utilizados para comprovar o perfil das células-tronco mesenquimais: aderência plástica, expressão de CD90 por citometria de fluxo ( > 90%) e capacidade de diferenciação em três linhagens mesodérmicas. Em D10, um pool destas células alogênicas foi infundido intravenosamente, na veia caudal, a uma concentração de 1 x 106 células/ animal num volume de 200 ul de solução salina. Em D14 ou D21, os animais foram eutanasiados e analisados quanto ao peso e conforme análises microscópico-laboratoriais. As análises histológicas foram realizadas por dois especialistas diferentes em estudo duplo-cego. Os parâmetros de ganho de peso e recuperação microscópica do tecido pulmonar foram analisados em cada grupo. Resultados: Nossos dados mostram que as células-tronco mesenquimais oriundas do tecido adiposo abdominal de ratos Wistar tiveram seu perfil fenotípico, capacidade de adesão plástica e diferenciação em 3 linhagens mesodérmicas estabelecidas inequivocamente, conforme estabelecido internacionalmente pela ISSCR. As células-tronco mesenquimais e o meio condicionado induziram: a recuperação clínica após tratamento; a reversão da inflamação e de fibrose pulmonar induzida pela bleomicina; a reversão da arteriopatia no parênquima pulmonar distal; a redução das concentrações de fibrinogênio, fator von Willebrand e PDGF (marcadores sorológicos); a diminuição da expressão de enzimas oxidantes; a diminuição da expressão de endotelina e a modulação da expressão da proteína de remodelamento (IL-17), da ativação dos fibroblastos TGF-B e da síntese de colágeno. Conclusão: Neste estudo, comprovamos que as terapias com células-tronco mesenquimais derivadas do tecido adiposo e com o meio condicionado foram eficazes na modulação dos processos inflamatórios e fibrogênicos no modelo induzido por bleomicina, agindo na ativação miofibroblástica, e, também, na restauração tecidual e endotelial. Além disso, o meio condicionado se mostrou tão eficiente quanto as células-tronco propriamente ditas, no efetivo remodelamento pulmonar, devendo ser considerado como uma proposta terapêutica viável e inovadora / Introduction: Idiopathic pulmonary fibrosis (IPF) is defined as a type of chronic interstitial fibrosing disease of unknown etiology limited to the lungs and presenting a histological pattern of usual interstitial pneumonia. The prevalence of IPF is estimated at approximately 20/100,000 in men and 13/100,000 in women, with the mean age of diagnosis being 67 years and the average survival is 2 to 5 years. It is estimated that 5 million people are affected worldwide. The current clinical treatment is associated with partial and transient improvement, with dubious or unsatisfactory results. In the surgical approach to IPF, pulmonary transplantation is a prominent feature, which is rare because of the scarcity of donors and the limitation of the teams capable of performing such procedures. Cell therapy is a therapeutic alternative with great potential for applicability in pulmonary fibrosis. Objectives: To use a model of bleomycin-induced lung fibrosis in rats to investigate the effects of mesenchymal stem cell (MSC) therapy and conditioned medium on lung remodeling in order to elucidate the mechanism of action of MSC and conditioned medium, in the reversion of pulmonary fibrosis. To do so, we aim to: 1) standardize the culture of mesenchymal stem cells and conditioned medium; 2) characterize the experimental model of lung fibrosis induced by bleomycin by optical microscopy before and after treatment with MSC and conditioned medium; 3) to evaluate the expression of serological biomarkers (Fibrinogen, Factor von Willebrand and PDGF); 4) to quantify the expression of proteins related to oxidative stress (NOS), pro-inflammatory and pro-fibrotic (IL-17 and TGF-beta) and pro-angiogenic cytokines (VEGF and endothelin) by immunohistochemistry; and 5) to quantify the deposition of collagen I and V fibers by immunofluorescence. Materials and methods: A total of 44 male albino Wistar rats weighing 250-300g and 8 weeks of age were used. Four experimental groups were composed of 10 animals, which participated in the experiment divided in three moments: D0, D10 and euthanasia (D14 or D21). In D0, orotracheal instillation of bleomycin at the dose of 1.5 U/ kg was performed; in D10 caudal vein infusion of mesenchymal stem cells at the dose of 106 MSC/ kg or 200 ul of conditioned medium was performed. To prepare the MSC, a mean of 1.2 g of adipose tissue was obtained, dissociated with type I collagenase and the mean cell count was 3.05 x 106 lymphomonuclear cells / g of adipose tissue. These cells were cultured for 21 days in DMEM-F12 Knockout medium supplemented with 10% fetal bovine serum. The following three criteria were used to prove the profile of mesenchymal stem cells: plastic adherence, expression of CD90 by flow cytometry ( > 90%) and differentiation capacity in three mesodermal lines. In D10, a pool of these allogeneic cells was infused intravenously into the caudal vein at a concentration of 1 x 106 cells / animal in a volume of 200 ul of saline. In D14 or D21 the animals were euthanized and analyzed for weight and microscopic-laboratory analyzes. Histological analyzes were performed by two different specialists in a double-blind study. The parameters of weight gain and microscopic recovery of lung tissue were analyzed in each group. Results: Our data show that the mesenchymal stem cells derived from the abdominal adipose tissue of Wistar rats had their phenotypic profile, plastic adhesion capacity and differentiation in 3 mesodermal lines established unequivocally, as established internationally by ISSCR. Mesenchymal stem cells and conditioned medium induced: clinical recovery after treatment; bleomycin-induced reversal of inflammation and pulmonary fibrosis; the reversal of arteriopathy in the distal pulmonary parenchyma; the reduction of fibrinogen, von Willebrand factor and PDGF concentrations (serologic markers); decreased expression of oxidizing enzymes; the reduction of endothelin expression and the modulation of the expression of the remodeling protein (IL-17), the activation of TGF-B fibroblasts and the synthesis of collagen. Conclusion: In this study we demonstrated that therapies with mesenchymal stem cells derived from adipose tissue and conditioned medium were effective in the modulation of inflammatory and fibrogenic processes in the bleomycin-induced model, acting to modulate myofibroblastic activation and also in tissue restoration and endothelial cells. In addition, the conditioned medium proved to be as efficient as the stem cells themselves, in effective pulmonary remodeling, and should be considered as a viable and innovative therapeutic proposal

Long-term oxygen therapy (LTOT) or home mechanical ventilation (HMV) can improve survival time in chronic respiratory failure. A national quality register could be an aid to identifying risk markers and optimizing therapy for respiratory failure. Aims: ▪To identify risk markers for chronic respiratory failure, especially when triggered by chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). ▪To predict sex-related differences in the future need of LTOT for COPD and to study sex related survival rate in COPD patients starting LTOT. ▪To investigate if HMV is more effective than LTOT alone in treating chronic respiratory failure caused by kyphoscoliosis. ▪To evaluate the use of quality indicators in LTOT. Methods: Swedish national registers for LTOT and HMV were established in 1987 and 1996 respectively. They were reconstructed in 2004 to form the web-based register Swedevox. Indications for LTOT were based on the guidelines from the Swedish Society for Respiratory Medicine. The incidence and prevalence of LTOT for COPD were measured annually from 1987 to 2000, and the future need for LTOT was estimated on the basis of the frequency of ever smoking in Sweden in 2001 in different age groups. A postal questionnaire on occupational exposures was completed by 181 patients with severe pulmonary fibrosis who started LTOT between 1997 and 2000, and by 757 controls. Odds ratios (ORs) were calculated. Time to death was evaluated in kyphoscoliotic patients starting HMV or LTOT alone in 1996-2004. Ten quality indicators were defined and evaluated based on data from patients starting LTOT in 1987-2005. Results: The incidence each year of LTOT in COPD patients increased more rapidly in women than in men (from 2.0 and 2.8/100,000 in 1987 to 7.6 and 7.1/100,000 in 2000 respectively, (p < 0.001)). Women ran a 1.9 times higher risk than men to develop chronic hypoxemia from COPD and had a higher survival rate during LTOT. In men, IPF was associated with exposure to birch dust with an OR 2.7, (95% confidence interval (CI) 1.30–5.65) and with hardwood dust, OR 2.7 (95% CI 1.14–6.52). Patients with kyphoscoliosis showed a better survival rate with HMV than with LTOT alone with a hazard ratio of 0.30 (95%CI 0.18-0.51), adjusted for age, sex, concomitant respiratory diseases, and blood gas levels. There were improvements in the following eight quality indicators for LTOT: access to LTOT, PaO2 ≤ 7.3 kPa without oxygen, no current smoking, low number of thoracic deformity patients without concomitant HMV, LTOT > 16 hours of oxygen/day, mobile oxygen equipment, reassessment of hypoxemia when LTOT was not started in a stable state COPD, and avoidance of continuous oral steroids in COPD. There was a decline in the indicator PaO2 > 8 kPa on oxygen. First-year survival rate in COPD was unchanged. Conclusions: The incidence and prevalence of LTOT increase more rapidly in women than in men. Survival rate during LTOT in COPD is better in women than in men. Exposure to birch and hardwood dust may contribute to the risk of IPF in men. Survival rate in patients with kyphoscoliosis was three times better with HMV than with LTOT alone. The national quality register for LTOT showed improvements in eight out of ten quality indicators. Levels for excellent quality in the indicators are suggested.

Submitted by DANIELE LOPES PEREIRA null (danielelopesp@hotmail.com) on 2016-05-11T22:02:11Z No. of bitstreams: 1 dissertação maio - 2016.doc: 36656128 bytes, checksum: 544a8bb80add41fb7e4e0faa6dc3b70c (MD5) / Rejected by Felipe Augusto Arakaki (arakaki@reitoria.unesp.br), reason: Solicitamos que realize uma nova submissão seguindo as orientações abaixo: A versão final da dissertação/tese deve ser submetida no formato PDF (Portable Document Format). O arquivo PDF não deve estar protegido e a dissertação/tese deve estar em um único arquivo, inclusive os apêndices e anexos, se houver. E também, o arquivo submetido está sem a folha de aprovações providenciada pela Pós-graduação. Lembramos que a versão submetida por você é considerada a versão final da dissertação/tese, portanto não poderá ocorrer qualquer alteração em seu conteúdo após a aprovação. Corrija estas informações e realize uma nova submissão contendo o arquivo correto. Agradecemos a compreensão. on 2016-05-13T16:38:51Z (GMT) / Submitted by DANIELE LOPES PEREIRA null (danielelopesp@hotmail.com) on 2016-08-12T21:37:08Z No. of bitstreams: 1 Terapia celular em fibrose pulmonar.pdf: 14681718 bytes, checksum: ddd650e002e44e6ba3817e66564c1581 (MD5) / Approved for entry into archive by Ana Paula Grisoto (grisotoana@reitoria.unesp.br) on 2016-08-15T19:52:38Z (GMT) No. of bitstreams: 1 pereira_dl_me_assis.pdf: 14681718 bytes, checksum: ddd650e002e44e6ba3817e66564c1581 (MD5) / Made available in DSpace on 2016-08-15T19:52:38Z (GMT). No. of bitstreams: 1 pereira_dl_me_assis.pdf: 14681718 bytes, checksum: ddd650e002e44e6ba3817e66564c1581 (MD5) Previous issue date: 2016-03-15 / A Fibrose Pulmonar (FP), também denominada Alveolite Fibrosante, é uma pneumopatia idiopática, crônica e irreversível, que acomete o tecido pulmonar promovendo a deposição de tecido fibroso cicatricial e consequente remodelamento da arquitetura pulmonar. Considerando a inexistência de um tratamento clínico curativo que não seja apenas paliativo, a terapia com células-tronco desponta como alternativa promissora no tratamento da fibrose pulmonar e diversas outras patologias. Neste contexto, este projeto propôs o emprego da terapia celular com células-tronco mesenquimais de tecido adiposo humano (CTMTA) e “pool” de células mononucleares da medula óssea (BMMC), isoladas ou conjuntamente, em modelo experimental de fibrose pulmonar. Foram utilizados 36 ratos Wistar divididos em 6 grupos. O grupo controle recebeu instilação intratraqueal de tampão fosfato. Cinco grupos foram instilados com bleomicina (2U/animal) para a indução da doença e, após 14 dias, submetidos ou não a diferentes tratamentos utilizando células mononucleares da medula óssea e/ou células-tronco mesenquimais de tecido adiposo, sendo que um grupo recebeu tratamento placebo com tampão fosfato. A análise histológica evidenciou o desenvolvimento de fibrose nos animais instilados com bleomicina (p<0,0001) e uma melhora do quadro fibrótico nos animais submetidos ao tratamento, independentemente do tipo celular utilizado (p<0,001). A ventilação pulmonar basal revelou a presença de esforço respiratório nos animais instilados com bleomicina (p=0,0260), porém nenhum tipo de terapia foi capaz de reverter esse quadro. Não houve diferença significativa entre o perfil de leucócitos encontrados no lavado broncoalveolar dos animais sadios e doentes, entretanto a terapia com CTMTA promoveu a redução da porcentagem de linfócitos e o aumento de macrófagos nos animais doentes. O tratamento com BMMC e CTMTA, realizado de modo isolado ou em conjunto, mostrou remissão significativa do quadro de fibrose instalado. / Pulmonary Fibrosis (PF), also known as fibrosing alveolitis, is an idiopathic, chronic, irreversible lung disease that affects the lung tissue by promoting the deposition of fibrous scar tissue and subsequent lung architecture remodeling. Considering the need for curative medical treatment that is not only palliative, stem cell therapy is emerging as a promising alternative for the treatment of pulmonary fibrosis and many other diseases. ln this context, it is proposed in this study the cell therapy with mesenchymal stem cells derived from human adipose tissue (CTMTA) in association with the pool of mononuclear bone marrow cells (BMMC) in an experimental model of pulmonary fibrosis. The disease was induced in 4 groups of Wistar rats (n = 6) by intratracheal bleomycin (2U/animal). 14 days after instillation, each group was subjected to a specific treatment with BMMC and CTMTA, isolated or combined mode, while a fourth group was treated with phosphate buffer. The control group was instilled and treated with phosphate buffer. Histological analysis showed the development of disease in animais instilled with bleomycin (p<0,0001) and untreated, and improvement in the fibrous framework of animais subjected to cell therapy (p<0,001 ). The basal ventilation revealed the presence of respiratory effort in animais instilled with bleomycin, submitted or not to therapy (p=0,0260). Treatment with BMMC and CTMTA, performed alone or in conjunction mode showed similar results, since both promoted remission of pulmonary fibrosis.

As doenças pulmonares intersticiais difusas caracterizam-se pela presença de um distúrbio ventilatório restritivo cuja intensidade está associada ao grau de extensão do comprometimento intersticial e consequentemente ao estágio da doença. As provas de função pulmonar em conjunto com o grau de comprometimento intersticial na TCAR são os principais métodos de avaliação utilizados para determinar o estágio da doença, bem como para acompanhar sua progressão e a resposta terapêutica. A densitovolumetria pulmonar realizada através da TC Helicoidal consiste em uma técnica objetiva e mais precisa que permite calcular a proporção de volume de pulmão com densidade aumentada pelo acometimento por fibrose sobre o volume de pulmão com densidade normal, ou seja, sem acometimento significativo dos interstícios. Na literatura, sugere-se –870 UH como o limiar de separação ideal para quantificação de fibrose pulmonar por tomografia computadorizada, acima do qual o pulmão seria considerado como apresentando aumento de densidade pela presença de fibrose ou de atenuação em vidro-fosco. O presente estudo comparou o limiar fixo em –870UH com a utilização de um limiar subjetivo ou variável selecionado com o auxílio de máscara de densidades em 30 pacientes com comprovação histológica FPI em relação as provas de função pulmonar. A correlação dos resultados da densitovolumetria pulmonar utilizando o limiar fixo (-870 HU) com as provas de função pulmonar foram de r= 0,265 com o VEF1, r=-0,450 com a CVF, r=-0,705 com a CPT e r= -0,305 com a DCO. Em comparação, as correlações entre os resultados da densitovolumetria pulmonar estabelecidos com base na seleção subjetiva de um limiar subjetivo foram: r= –0,347 com o VEF1, r= - 0,534 com a CVF, r= -0,734 com a CPT e r= –0,413 com a DCO. Tanto as medidas objetivas como subjetivas da extensão da fibrose realizadas pela densitovolumetria apresentaram boa correlação com as medidas funcionais que expressam restrição. As correlações foram fracas, quando correlacionadas com medidas funcionais que não expressam a extensão da fibrose pulmonar. A densitovolumetria pode proporcionar uma técnica mais precisa que a simples análise subjetiva das imagens de tomografia computadorizada de alta resolução em pacientes com FPI, sendo assim mais efetiva na avaliação evolutiva de cada paciente. / Diffuse interstitial pulmonary diseases are characterized by restrictive lung disorders whose intensity is associated with the extent of interstitial involvement and, consequently, the stage of the disease. Pulmonary function tests and HRCT assessment of the degree of interstitial involvement are the primary methods to establish the stage of the disease, to follow up its progression, and to evaluate therapeutic response. Pulmonary densitovolumetry using helical CT is an objective and accurate technique to calculate the proportion of volume of lung with increased density due to fibrosis with relation to volume of lung with normal density, that is, without significant interstitial involvement. Studies in the literature suggest - 870 UH as the ideal segmentation threshold to assess pulmonary fibrosis using CT; above this value, increased density due to fibrosis or ground-glass opacity should be considered. In this study, the use of a -870 HU fixed threshold was compared with the use of a subjective or variable threshold selected with the aid of a density mask in 30 patients with a histologic diagnosis of IPF, and results were correlated with pulmonary function test results. Correlations between pulmonary densitovolumetry using the fixed threshold (-870 HU) and pulmonary function tests were r= 0.265 for FEV1, r=-0.450 for FVC, r=-0.705 for TLC and r= -0.305 for DLCO. When pulmonary densitovolumetry with selection of a subjective threshold was used, results were: r= –0.347 for FEV1, r= -0.534 for FVC, r= -0.734 for TLC and r= –0.413 for DLCO. Both objective and subjective measurements of the extent of fibrosis using densitovolumetry had a good correlation with results of functional tests that indicate restriction. Correlations were weak with functional measurements that do not indicate the extent of pulmonary fibrosis. Densitovolumetry may be a more accurate technique than the simple subjective analysis of high-resolution CT images in patients with IPF, and may be, therefore, more effective in the evaluation of disease progression.

Fundação de Amparo à Pesquisa do Estado do Rio de Janeiro / A fibrose pulmonar é uma doença pulmonar crônica caracterizada pelo acúmulo excessivo de matriz extracelular (MEC) e um remodelamento na arquitetura pulmonar. Embora já se saiba da participação do estresse oxidativo e da inflamação na fibrose de forma isolada, é importante observar como se comporta o estresse oxidativo na fibrose quando esta ocorre associada a uma doença de base. O presente estudo teve como objetivo investigar o perfil inflamatório e oxidativo na fibrose pulmonar associado ao enfisema pulmonar prévio. Camundongos C57BL/6 foram divididos em três grupos: grupo controle (n=5) que receberam salina intranasal (50 l) e foram sacrificados no 21 dia; grupo bleomicina (BLEO) (n=15) que receberam bleomicina intratraqueal (0.1 U/animal) no dia 0 e foram sacrificados nos 7 (n=5), 14 (n=5) e 21 (n=5) dias e grupo PPE (elastase) + BLEO (n=21) que receberam elastase (3U/animal) e após 14 dias receberam bleomicina e foram sacrificados nos 14(n=7), 21 (n=7), 28 (n=7) e 35 (n=7) dias. Foram realizadas análises histológicas através de H&E e picro-sirius; análises bioquímicas para superóxido dismutase (SOD), catalase (CAT), glutationa peroxidase (GPx) e glutationa-S-transferase (GST) e ELISA para Interleucina (IL)-1&#946; e IL-6. A fibrose pulmonar ocorreu a partir do 14 dia (p<0.001) e o enfisema concomitante a fibrose pulmonar a partir do 28 dia (p<0.001) e um aumento de fibras colágenas no grupo BLEO 21(p<0.001) e PPE + BLEO 21(p<0.001). As enzimas antioxidantes CAT (p<0.01), SOD (p<0.01) e GPx (p<0.01) reduziram e a GST aumentou no grupo BLEO 21 dias (p<0.05). No grupo PPE + BLEO 21 dias houve redução das enzimas antioxidantes CAT, SOD, GPx (p<0.05) e GST. Os níveis de óxido foram altos nos grupos BLEO 21 dias (p<0.01) e PPE + BLEO 21 dias (p<0.01). A IL-1&#946; mostrou-se elevada no grupo BLEO 7 dias quando comparado ao controle (p<0.001) e ao grupo PPE + BLEO 7 dias (p<0.01). Concluímos que a resposta inflamatória inibiu a ação do sistema antioxidante contribuindo para o agravamento da lesão. Isso sugere que terapias anti-inflamatórias podem contribuir tanto para redução da resposta inflamatória quanto de forma indireta no sistema antioxidante. / Pulmonary fibrosis (PF) is a chronic lung disease characterized by excessive accumulation of extracellular matrix (ECM) and remodeling in the lung architecture. Although it is already known the role of oxidative stress and inflammation in the isolated pulmonary fibrosis, it is important to observe how it behaves oxidative stress in pulmonary fibrosis when it occurs associated with an underlying disease. The present study aimed to investigate the inflammatory status and oxidative pulmonary fibrosis associated with pulmonary emphysema prior. C57BL / 6 mice were divided into three groups: control group (n = 5) who received intranasal saline (50l) and were sacrificed at 21 days, bleomycin (BLEO) group (n=15) who received intratracheal bleomycin (0.1U/animal) in the day 0 and were sacrificed at 7 (n=5), 14 (n=5) and 21 (n=5) days and the PPE + BLEO group (n=21) received elastase (PPE)(3U/animals) and 14 days after receiving bleomycin and were sacrificed at 14 (n = 7), 21 (n = 7) 28 (n = 7) and 35 (n = 7) days. Histological analysis was achieved using H&E and Sirius red staining; biochemical analysis for superoxide dismutase (SOD), catalase (CAT), glutathione peroxidase (GPx) and glutathione-S-transferase (GST) and ELISA for IL-1&#946; and IL-6 were conducted. Pulmonary fibrosis occurred from day 14 (p<0.001) emphysema and pulmonary fibrosis from day 28 (p <0.001) and occurred an increase of collagen fibers in the BLEO group 21days (p<0.001) and PPE + BLEO 21days (p <0.001). Antioxidant enzymes CAT (p <0.01), SOD (p <0.01), and GPx (p <0.01) were reduced and GST increased in the BLEO group 21 days (p<0,05). In the PPE + BLEO group 21 days occurred an decreased antioxidant enzymes CAT, SOD, GPx (p <0.05), and GST. Oxide levels were higher in the BLEO groups 21 days (p <0.01), and PPE + BLEO group 21 days (p <0:01). IL-1&#946; was elevated in the group BLEO 7 days when compared to control (p <0.001) and the PPE + BLEO group 7 days (p<0.01). The inflammatory response inhibited the action of the antioxidant system contributes to the aggravation of the injury. This suggests that anti-inflammatory therapies may contribute to reducing the inflammatory response as indirectly to the antioxidant system.